PAVmed (NASDAQ:PAVM) reported quarterly losses of $(1.17) per share which missed the analyst consensus estimate of $(0.70) by 67.14 percent. This is a 44.29 percent increase over losses of $(2.10) per share from the same period last year. The company reported quarterly sales of $22.000 thousand which missed the analyst consensus estimate of $74.000 thousand by 70.27 percent. This is a 175.00 percent increase over sales of $8.000 thousand the same period last year.